Literature DB >> 11884464

Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines.

Yasuko Asahi1, Tomoki Yoshikawa, Izumi Watanabe, Takuya Iwasaki, Hideki Hasegawa, Yuko Sato, Shin-ichiro Shimada, Masanobu Nanno, Yoshiaki Matsuoka, Makoto Ohwaki, Yoichiro Iwakura, Yujiro Suzuki, Chikara Aizawa, Tetutaro Sata, Takeshi Kurata, Shin-ichi Tamura.   

Abstract

The role of secretory IgA in conferring cross-protective immunity was examined in polymeric (p)IgR knockout (KO) mice immunized intranasally with different inactivated vaccines prepared from A/PR/8/34 (H1N1), A/Yamagata/120/86 (H1N1), A/Beijing/262/95 (H1N1), and B/Ibaraki/2/85 viruses and infected with the A/PR/8/34 virus in the upper respiratory tract (RT)-restricting volume. In wild-type mice, immunization with A/PR/8/34 or its variant (A/Yamagata/120/86 and A/Beijing/262/95) vaccines conferred complete protection or partial cross-protection against infection, while the B-type virus vaccine failed to provide protection. The protection or cross-protection was accompanied by an increase in the nasal A/PR/8/34 hemagglutinin-reactive IgA concentration, which was estimated to be >30 times the serum IgA concentration and much higher than the nasal IgG concentration. In contrast, the blockade of transepithelial transport of dimeric IgA in pIgR-KO mice reduced the degree of protection or cross-protection, in parallel with the marked increase in serum IgA concentration and the decrease in nasal IgA concentration (about 20 and 0.3 times those in wild-type mice, respectively). The degree of the reduction of protection or cross-protection was moderately reversed by the low but non-negligible level of nasal IgA, transudates from the accumulated serum IgA. These results, together with the absence of the IgA-dependent cross-protection in the lower RT and the unaltered level of nasal or serum IgG in wild-type and pIgR-KO mice, confirm that the actively secreted IgA plays an important role in cross-protection against variant virus infection in the upper RT, which cannot be substituted by serum IgG.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11884464     DOI: 10.4049/jimmunol.168.6.2930

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  65 in total

1.  H1N1 infection associated with persistent lower respiratory tract illness in an infant with isolated IgA deficiency.

Authors:  Ankur Priyadarsi; Jhuma Sankar
Journal:  BMJ Case Rep       Date:  2012-02-21

Review 2.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

3.  Parenteral nutrition induces organ specific alterations in polymeric immunoglobulin receptor levels.

Authors:  Yoshifumi Sano; F Enrique Gomez; Joshua L Hermsen; Woodae Kang; Jinggang Lan; Yoshinori Maeshima; Kenneth A Kudsk
Journal:  J Surg Res       Date:  2008-01-29       Impact factor: 2.192

4.  Nasal immunity is an ancient arm of the mucosal immune system of vertebrates.

Authors:  Luca Tacchi; Rami Musharrafieh; Erin T Larragoite; Kyle Crossey; Erik B Erhardt; Samuel A M Martin; Scott E LaPatra; Irene Salinas
Journal:  Nat Commun       Date:  2014-10-22       Impact factor: 14.919

Review 5.  Fast vaccine design and development based on correlates of protection (COPs).

Authors:  Cécile van Els; Siri Mjaaland; Lisbeth Næss; Julia Sarkadi; Eva Gonczol; Karen Smith Korsholm; Jon Hansen; Jørgen de Jonge; Gideon Kersten; Jennifer Warner; Amanda Semper; Corine Kruiswijk; Fredrik Oftung
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 6.  Innate sensors of influenza virus: clues to developing better intranasal vaccines.

Authors:  Takeshi Ichinohe; Akiko Iwasaki; Hideki Hasegawa
Journal:  Expert Rev Vaccines       Date:  2008-11       Impact factor: 5.217

7.  Adjuvanted influenza vaccine administered intradermally elicits robust long-term immune responses that confer protection from lethal challenge.

Authors:  Maria del P Martin; Shaguna Seth; Dimitrios G Koutsonanos; Joshy Jacob; Richard W Compans; Ioanna Skountzou
Journal:  PLoS One       Date:  2010-05-28       Impact factor: 3.240

Review 8.  Mouse models for the study of mucosal vaccination against otitis media.

Authors:  Albert Sabirov; Dennis W Metzger
Journal:  Vaccine       Date:  2008-02-04       Impact factor: 3.641

9.  Highly sensitive detection of influenza virus by boron-doped diamond electrode terminated with sialic acid-mimic peptide.

Authors:  Teruhiko Matsubara; Michiko Ujie; Takashi Yamamoto; Miku Akahori; Yasuaki Einaga; Toshinori Sato
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-25       Impact factor: 11.205

10.  Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses.

Authors:  Hideki Hasegawa; Takeshi Ichinohe; Akira Ainai; Shin-Ichi Tamura; Takeshi Kurata
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.